Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Operating Leases (2019 - 2023)

Marker Therapeutics (MRKR) has disclosed Operating Leases for 5 consecutive years, with $6.8 million as the latest value for Q1 2023.

  • Quarterly Operating Leases fell 41.78% to $6.8 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $6.8 million through Mar 2023, down 41.78% year-over-year, with the annual reading at $7.0 million for FY2022, 37.42% down from the prior year.
  • Operating Leases for Q1 2023 was $6.8 million at Marker Therapeutics, down from $7.0 million in the prior quarter.
  • The five-year high for Operating Leases was $12.0 million in Q3 2021, with the low at $226111.0 in Q1 2020.
  • Average Operating Leases over 5 years is $7.4 million, with a median of $9.5 million recorded in 2020.
  • The sharpest move saw Operating Leases tumbled 66.25% in 2020, then soared 5083.22% in 2021.
  • Over 5 years, Operating Leases stood at $280247.0 in 2019, then surged by 4134.99% to $11.9 million in 2020, then dropped by 5.23% to $11.2 million in 2021, then plummeted by 37.42% to $7.0 million in 2022, then dropped by 3.06% to $6.8 million in 2023.
  • According to Business Quant data, Operating Leases over the past three periods came in at $6.8 million, $7.0 million, and $7.2 million for Q1 2023, Q4 2022, and Q3 2022 respectively.